RxDoctor Payments Data

Christine Greiss, DO

Physical Medicine & Rehabilitation · Edison, NJNPI 1043537947

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,569 of the $28,496 with a category attached, or 96.7%. Otsuka America Pharmaceutical, Inc. accounts for 67.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $11,139 and has fallen 99.7% since, to $32 in 2025. Among physical medicine & rehabilitation clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,496in general payments, 2019–2025

Across 33 payments — averaging $863.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$19K
  • Avanir Pharmaceuticals, Inc.$9K
  • AbbVie$109
  • Axsome Therapeutics, Inc.$16
  • Sunovion Pharmaceuticals Inc.$13

What the payments were for

  • Speaking & faculty fees$27,56997%
  • Travel & lodging$550%
  • Food & beverage$8723%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,496 in reported general payments places this provider in the 95th percentile of 434 physical medicine & rehabilitation providers in New Jersey.

See all physical medicine & rehabilitation providers in New Jersey

Medicare billing

Part B allowed, 2024
$79,607
Medicare patients
264
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine13$20,229
EliquisApixaban15$8,523
Memantine Hcl47$676
Mirtazapine15$543
Propranolol Hcl17$341
Escitalopram Oxalate13$332
Duloxetine Hcl14$300
Baclofen16$243
Amlodipine Besylate13$176
Atorvastatin Calcium23$156
Trazodone Hcl24$145
Pantoprazole Sodium11$51
ClopidogrelClopidogrel Bisulfate11$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$9,088$20,22913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 physical medicine & rehabilitation providers in New Jersey.

Other physical medicine & rehabilitation in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →